Russian Heart Failure Journal 2011year Effects of aldosterone blockade in patients with heart failure: a modern approach to the problem – eplerenone (part II)

To access this material please log in or register

Register Authorize

Effects of aldosterone blockade in patients with heart failure: a modern approach to the problem – eplerenone (part II)

Mareev V. Y.1, Skvortsov A. A.2
1 –Federal State Budgetary Educational Institution of Higher Professional Education “M. V. Lomonosov Moscow State University”, Leninskie Gory 1, GSP-1, Moscow 119992
2 – Federal State Budgetary Institution, “Russian Cardiology Research and Production Complex” of the RF Ministry of Health Care, 3rd Cherepkovskaya 15a, Moscow 121552

Keywords: aldosterone, CHF

DOI: 10.18087/ rhfj.2011.4.1485

83. Pitt B, White H, Nicolau J et al; EPHESUS Investigators. Eplerenone reduced mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46 (3):425–431.
84. Pitt B, Gheorghiade M, Zannad F et al; On behalf of the EPHESUS Investigators. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%. Eur J Heart Fail. 2006;8 (3):295–301.
85. Solomon SD, Zelenkofske S, McMurray JJ et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352 (25):2581–2588.
86. White PC. Aldosterone: direct effects on and production by the heart. J Clin Endocrinol Metab. 2003;88 (6):2376–2383.
87. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351 (6):543–551.
88. Svensson M, Gustafsson F, Galatius S et al. Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart fai­lure: retrospective study. BMJ. 2003;327 (7424):1141–1142.
89. Ko DT, Juurlink DN, Mamdani MM et al. Appropriateness of spironolactone prescribing in heart failure patients: a population based study. J Card Fail. 2006;12 (3):205–210.
90. Wrenger E, Muller R, Moesenthin M et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ. 2003;327 (7407):147–149.
91. Schepkens H, Vanholder R, Billiouw JM et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110 (6):438–441.
92. Castellino P, Simonson DC, DeFronzo RA. Adrenergic modulation of potassium metabolism during exercise in normal and diabetic humans. Am J Physiol. 1987;252 (1 Pt 1):E68–76.
93. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345 (23):1667–1675.
94. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362 (9386):767–771.
95. Pitt B, Bakris G, Ruilope LM et al. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008;118 (16):1643–1650.
96. Delgado-Almeida A, Delgado-Leon C. Changes in plasma ionized calcium and RBC K content in severe hyperkalemia: new electrocardiographic concept. Circulation. 2006;114 (Suppl II):II-466. Abstract.
97. Ahmed A, Pitt B, Rahimtoola SH et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol. 2008;123 (2):138–146.
98. Nolan J, Batin P, Andrews R et al. Prospective study of heart rate variability and mortality in chronic heart failure; results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-HEART). Circulation. 1998;98 (15):1510–1516.
99. Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol. 2004;43 (2):155–161.
100. Tsutamoto T, Wada A, Maeda K et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37 (5):1228–1233.
101. Ikeda U, Kanbe T, Nakayama I et al. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol. 1995;290 (2):69–73.
102. Brown NJ, Kim KS, Chen YQ et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab. 2000;85 (1):336–344.
103. De Angelis N, Fiordaliso F, Latini R et al. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in sdult normotensive rat. J Mol Cell Cardiol. 2002;34 (12):1655–1665.
104. Struthers AD. Aldosterone-induced vasculopathy: a new reversible cause of cardiac death. J Renin Angiotensin Aldosterone Syst. 2001;2 (4):211–214.
105. Tsutamoto T, Wada A, Maeda K et al. Spironolactone inhibits the trans­cardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol. 2000;36 (3):838–844.
106. Hayashi M, Tsutamoto T, Wada A et al. Immediate administration of mine­ralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107 (20):2559–2565.
107. Zannad F, Ketelsiegers JM, Schiffrin EL et al. The effect of eplerenone on markers of cardiac fibrosis: insights from EPHESUS. J Am Coll Cardiol. 2004;43 (Suppl A):A200.
108. Ketelsiegers JM, Zannad F, Schiffrin EL et al. The effect of eplerenone on the cytokine osteopontin in post-AMI heart failure: an EPHESUS substudy Eur Heart J. 2004;25 (Suppl):485.
109. Trueblood NA, Xie Z, Cormmunal C et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res. 2001;88 (10):1080–1087.
110. Zohar R, Zhu B, Liu P et al. Increased cell death in osteopontin-deficient cardiac fibroblasts occurs by a caspase 3‑in-dependent pathway. Am J Physiol Heart Circ Physiol. 2004;287 (4):H1730–1739.
111. Udelson JE, Feldman AM, Greenberg B et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail. 2010;3 (3):347–353.
112. Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart. 2004;90 (7):765–770.
113. Скворцов A. А., Мареев В. Ю., Орлова Я. А. и др. Влияние длительной терапии спиронолактоном на параметры суточной вариабельности ритма сердца и желудочковые аритмии у больных умеренной и тяжелой ХСН, находящихся на оптимальной терапии. Кардиология. 2008;48 (2):62–74.
114. Zannad F, McMurray JJ, Krum H et al. for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364 (1):11–21.
115. Zannad F, McMurray JJV, Drexler H et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail. 2010;12 (6):617–622.
116. Скворцов А. А., Мареев В. Ю., Беленков Ю. Н. Место блокаторов рецепторов ангиотензина II в лечении больных ХСН. Сердце 2008;7 (5):275–283.
117. Беленков Ю. Н., Мареев В. Ю., Скворцов А. А. Всегда ли необходима тройная комбинация в лечении больных ХСН? Выбор третьего нейрогормонального блокатора. Терапевтический архив. 2008;80 (9):5–12.
Mareev V. Y., Skvortsov A. A. Effects of aldosterone blockade in patients with heart failure: a modern approach to the problem – eplerenone (part II). Russian Heart Failure Journal. 2011;12(4):222-227.

To access this material please log in or register

Register Authorize
Ru En